Positive Preclinical Results Unveiled for DPH001

August 23, 2023, Disruptive Pharma Announcement by Peter Åsberg

We’re delighted to share positive results from our recent preclinical study for DPH001. With our innovative MMC technology, researchers at Disruptive Pharma AB have engineered an improved sorafenib formulation intended for the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC). DPH001, confirms its bioequivalent exposure profile at 50% API dose compared to NEXAVAR®. Our data show that the MMC sorafenib formulation of DPH001 achieved the 2X absorption and reduced inter-animal variability which was the goal of the PK study. The animals were given MMC sorafenib formulation, at 50% API dose, and NEXAVAR® at standard API dose. CEO Peter Åsberg: “we look forward to continue developing DPH001 which will bring an important improvement for patients with HCC/RCC. We believe it can have a major impact on the market and have a positive impact for the patients in terms of an improved side-effect profile undergoing sorafenib treatment. We’re really excited about our upcoming work and the commercial opportunities we see that DPH001 can bring as well as being a demonstrator on how the patented MMC technology may be utilized to create improved versions of marketed products.”

Furthermore, Åsberg highlighted the broader potential of Disruptive Pharma’s MMC technology, which could pave the way for enhanced versions of existing products, stating:

“DPH001 serves as a prime example of how our patented MMC technology can be harnessed to create superior iterations of marketed products. This not only demonstrates our commitment to innovation but also underscores our dedication to improving patients’ lives.”

Disruptive Pharma CEO Peter Åsberg

What is MMC?

Pharma grade mesoporous magnesium carbonate (Pharma MMC) is a patented, safe and soluble drug delivery system that can be used to stabilize poorly soluble drugs in an amorphous state with beneficial oral absorption properties. Further, the controlled particle size of the drug loaded Pharma MMC ensures excellent flowability and downstream processing properties.

Pharma MMC gives existing products extended life and improved performance.
Pharma MMC facilitates novel drug development with one formulation from pre-clinical, though clinical and to commercial stage.

Compared to other mesoporous drug delivery technologies Pharma MMC offers an attractive combination of

High drug load: 25-35% (potentially higher)
Improved bioavailability
Long term amorphous stability
Superior flowability (good-excellent)
No residual MMC after delivery of drug
Rapid instant / modified release

MORE INFORMATION ON PHARMA MCC